Egetis Therapeutics: A potential indication expansion - Redeye

Redeye is encouraged by Egetis Therapeutic’s announcement earlier today, stating that the FDA has granted Orphan Drug Designation (ODD) to Emcitate for treatment of Resistance to Thyroid Hormone type beta (RTH-β).

Länk till analysen i sin helhet: https://www.redeye.se/research/833771/egetis-therapeutics-a-potential-indication-expansion?utm_source=finwire&utm_medium=RSS